Clinical Trials

NCT07185997 | RECRUITING | PHASE3
480 participants

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-03
Start Date:
2025-12-17
Completion:
2029-02-28
Conditions
  • Non-Small-Cell Lung Cancer
  • Metastatic Non-Small-Cell Lung Cancer
  • Advanced Non-Small-Cell Lung Cancer
  • EGFR P-Loop and Alpha C-Helix Compressing
  • EGFR PACC
  • EGFR Uncommon Mutations
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page